Find out if this study is right for you.
The PROCADE Trial is for men with metastatic castration-resistant prostate cancer (mCRPC).
Do I Qualify?
Do I Qualify?
Prostate cancer is the 2nd most common cancer in men and the 4th most common cancer overall.
Metastatic castration-resistant prostate cancer (mCRPC) is when the cancer has spread beyond the prostate and initial hormone therapy is no longer effective in stopping or slowing the disease.
Source: International Agency for Research on Cancer (IARC) Global Cancer Observatory- Are you a male, age 18 years or older?
- Have you been diagnosed with prostate cancer?
- Has your cancer progressed, despite treatment?
Find out more about the PROCADE Trial
Learn More
©2024 Hinova Pharmaceuticals Inc. All rights reserved.
©2024 Hinova Pharmaceuticals Inc. All rights reserved.